Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:50866
Name oral squamous cell carcinoma
Definition An oral cavity cancer that has_material_basis_in squamous cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer oral squamous cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047R Palbociclib oral squamous cell carcinoma resistant detail...
PIK3CA H1047R Ribociclib oral squamous cell carcinoma decreased response detail...
PIK3CA H1047R Abemaciclib oral squamous cell carcinoma decreased response detail...
PIK3CA H1047L Palbociclib + PF-04691502 oral squamous cell carcinoma sensitive detail...
PIK3CA H1047L PF-04691502 oral squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047L Palbociclib oral squamous cell carcinoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00904345 Phase II Cetuximab Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) Terminated USA 0
NCT01195922 Phase Ib/II Sirolimus Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT01540682 Phase I Alisertib + Cetuximab MLN8237 in Head and Neck Cancer Completed USA 0
NCT01553851 Phase II Trametinib GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed USA 0
NCT01612351 Phase II Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Active, not recruiting USA 0
NCT01732640 Phase Ib/II Afatinib + Carboplatin + Paclitaxel Cisplatin A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. Terminated USA 0
NCT01783587 Phase I Afatinib Docetaxel Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Completed USA 0
NCT01810913 Phase II Docetaxel Cisplatin Cetuximab + Docetaxel Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Recruiting USA | CAN 1
NCT01824823 Phase II Afatinib Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence Terminated USA 0
NCT01914900 Phase II Cisplatin + Docetaxel + Fluorouracil Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Completed ITA 0
NCT01927744 Phase II Docetaxel + Erlotinib Cisplatin Docetaxel Carboplatin Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection Recruiting USA 0
NCT02196168 Phase II Adavosertib Cisplatin Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated CAN 0
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Active, not recruiting USA 0
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated USA 0
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Completed 0
NCT02381535 Phase I Cisplatin Onalespib Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting USA | CAN 0
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02473731 Phase I CDX-3379 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Completed USA 0
NCT02499120 Phase II Palbociclib Cetuximab Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer Completed USA | SVK | ROU | POL | ITA | HUN | ESP | CZE 7
NCT02499328 Phase Ib/II Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Active, not recruiting USA | ITA | GBR | ESP | DEU | BEL 0
NCT02551159 Phase III Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Completed USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT 9
NCT02585973 Phase I Adavosertib + Cisplatin Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Completed USA 0
NCT02586207 Phase I Cisplatin + Pembrolizumab Pembrolizumab in Combination With CRT for LA-SCCHN Active, not recruiting USA 0
NCT02734537 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting USA 0
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed USA | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS 4
NCT02764593 Phase I Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Active, not recruiting USA 0
NCT02775812 Phase I Cisplatin + Pembrolizumab Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT02777385 Phase II Cisplatin + Pembrolizumab Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Completed USA 0
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Completed USA 0
NCT02873819 Phase II MAGE-A3 vaccine Cyclophosphamide + Poly ICLC + Sargramostim Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Completed USA | POL | HUN | ESP 3
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Terminated USA 0
NCT02919683 Phase II Nivolumab Ipilimumab + Nivolumab Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting USA 0
NCT02993991 Phase I Durvalumab + Mocetinostat Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity Withdrawn CAN 0
NCT02994069 Phase II Cisplatin Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers Active, not recruiting USA 0
NCT03021993 Phase II Nivolumab Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Completed USA 0
NCT03162731 Phase I Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Completed USA 0
NCT03238365 Phase I Nivolumab + Tadalafil Nivolumab Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Completed USA 0
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Completed USA | DEU 0
NCT03258008 Phase II ISA101b + Utomilumab Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Terminated USA 0
NCT03317327 Phase Ib/II Nivolumab REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT) Recruiting NOR 0
NCT03341936 Phase II Lirilumab + Nivolumab Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA 0
NCT03342352 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Withdrawn 0
NCT03342911 Phase II Carboplatin + Nivolumab + Paclitaxel Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Completed USA 0
NCT03349710 Phase III Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed USA | TUR | POL | ITA | FRA | ESP 4
NCT03356223 Phase II Abemaciclib Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) Completed FRA 0
NCT03370276 Phase Ib/II Cetuximab + Nivolumab Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03381183 Phase Ib/II Cyclophosphamide + Durvalumab + Tremelimumab IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03383094 Phase II Pembrolizumab Cisplatin + Radiotherapy Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Recruiting USA 0
NCT03386838 Phase III Linrodostat + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Withdrawn USA 0
NCT03406247 Phase II Ipilimumab + Nivolumab Nivolumab Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) Recruiting FRA 0
NCT03480672 Phase II Cisplatin Cisplatin + Pembrolizumab Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma Active, not recruiting DEU 0
NCT03515538 Phase II Cisplatin + RRx-001 RRx-001 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Completed USA 0
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Completed USA 0
NCT03575234 Phase Ib/II Cyclophosphamide + IRX-2 + Nivolumab Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Withdrawn USA 0
NCT03575598 Phase I Nivolumab + Sitravatinib Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Completed CAN 0
NCT03576417 Phase III Cisplatin Cisplatin + Nivolumab A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) Active, not recruiting FRA 0
NCT03618134 Phase Ib/II Durvalumab Durvalumab + Tremelimumab Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Terminated USA 0
NCT03625323 Phase II Eftilagimod alpha + Pembrolizumab Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) Active, not recruiting USA | GBR | ESP | AUS 1
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03719690 Phase II Tipifarnib Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) Completed USA | NOR | NLD | ITA | GRC | GBR | ESP | DNK | DEU | BEL | AUT | AUS 4
NCT03723967 Phase II Carboplatin + Durvalumab + Paclitaxel FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE) Completed FRA 0
NCT03784066 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) Active, not recruiting BEL 0
NCT03818061 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA) Active, not recruiting FRA 0
NCT03818542 Phase I ABBV-927 ABBV-368 Budigalimab A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma Terminated USA 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | ISR | FRA | ESP | CAN | BEL | AUS 4
NCT03829722 Phase II Carboplatin + Nivolumab + Paclitaxel Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer Completed USA 0
NCT03865082 Phase II IMO-2125 + Ipilimumab + Nivolumab Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Active, not recruiting USA 0
NCT03906526 Phase I Motolimod Motolimod + Nivolumab Nivolumab A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer Terminated USA 0
NCT03944915 Phase II Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) Recruiting USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA 0
NCT04106362 Phase II Cisplatin Cetuximab + Cisplatin Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma Terminated USA 0
NCT04169074 Phase II Abemaciclib Abemaciclib + Nivolumab Modulation of the Tumor Microenvironment by Abemaciclib in Operable HPV-Negative Head and Neck Cancer (HNC) Recruiting USA 0
NCT04183166 Phase I TG4050 A Clinical Trial Evaluating TG4050 in Head and Neck Cancer Recruiting USA | GBR | FRA | ESP 0
NCT04193293 Phase Ib/II Duvelisib + Pembrolizumab A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer Terminated USA 0
NCT04196283 Phase I ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed USA | NLD | ISR | FRA | ESP | DEU 0
NCT04199104 Phase III Lenvatinib + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) Active, not recruiting USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS 7
NCT04278092 Phase II Cetuximab + Paclitaxel Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure Recruiting AUT 0
NCT04282109 Phase II Nivolumab + Paclitaxel Cetuximab + Paclitaxel Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX) Completed ESP 0
NCT04290546 Phase I CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept CIML-NK cells + Nogapendekin alfa inbakicept CIML NK Cell in Head & Neck Cancer Active, not recruiting USA 0
NCT04428047 Phase II Bintrafusp alfa Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING) Terminated FRA 0
NCT04445064 Phase II IO102 IO103 Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901) Unknown status BEL 0
NCT04453046 Phase I Pembrolizumab Hemopurifier Plus Pembrolizumab in Head and Neck Cancer Terminated USA 0
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Terminated USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN 4
NCT04533750 Phase I Peposertib Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting USA 0
NCT04534205 Phase II BNT113 + Pembrolizumab Pembrolizumab A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) Recruiting USA | TUR | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 5
NCT04576091 Phase I Elimusertib + Pembrolizumab Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Active, not recruiting USA 0
NCT04588038 Phase I NT-I7 NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Recruiting USA 0
NCT04590963 Phase III Cetuximab Cetuximab + Monalizumab Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) Active, not recruiting USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 6
NCT04624113 Phase Ib/II Pembrolizumab + Tazemetostat Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Terminated USA 0
NCT04633278 Phase II Pembrolizumab + Vidutolimod CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Terminated USA 0
NCT04634825 Phase II MGA271 + Retifanlimab MGA271 + MGD013 Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Terminated USA | POL | HUN | ESP | BGR | AUS 1
NCT04643379 Phase II Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Active, not recruiting USA 0
NCT04665843 Phase II Atezolizumab + Tiragolumab Atezolizumab A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) Active, not recruiting USA | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE 3
NCT04671667 Phase II Cisplatin Pembrolizumab Carboplatin Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04681469 Phase II Dostarlimab-gxly + Niraparib Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (PRIME) Recruiting ITA 0
NCT04722523 Phase I Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Recruiting USA 0
NCT04747054 Phase III Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) Recruiting FRA 0
NCT04754321 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer Recruiting USA 0
NCT04795713 Phase I MT-6402 Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 Terminated USA 0
NCT04811027 Phase II Eftilagimod alpha + Pembrolizumab Pembrolizumab Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) Active, not recruiting USA | ROU | GBR | ESP | DNK | DEU | BEL | AUS 1
NCT04831320 Phase II Nab-paclitaxel + Nivolumab Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor Active, not recruiting USA 0
NCT04858269 Phase II Carboplatin + Paclitaxel + Pembrolizumab First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Recruiting USA 0
NCT04862650 Phase II Carboplatin + Cemiplimab + Paclitaxel Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Suspended USA 0
NCT04892173 Phase III Cetuximab NBTXR3 NBTXR3 With or Without Cetuximab in LA-HNSCC Recruiting USA | SWE | ROU | ISR | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT 9
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Recruiting USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS 4
NCT04966481 Phase III Cetuximab + Palbociclib Cetuximab Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor Recruiting USA 0
NCT04969861 Phase II NKTR-214 + Pembrolizumab Pembrolizumab BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Terminated USA | ITA | GRC | AUT 0
NCT05053737 Phase Ib/II Atezolizumab Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC Suspended USA 0
NCT05057247 Phase II Docetaxel + Duvelisib Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Active, not recruiting USA 0
NCT05061420 Phase II Cetuximab + Pembrolizumab + THOR-707 Cetuximab + THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | ARG 3
NCT05136196 Phase II Cabozantinib + Nivolumab BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Suspended USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05172245 Phase I Cisplatin + Ipatasertib Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Recruiting USA | CAN 0
NCT05271604 Phase II BA3021 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting USA 0
NCT05280314 Phase II IO102-IO103 + Pembrolizumab Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors Recruiting USA | FRA | ESP | DNK | DEU | AUS 0
NCT05287113 Phase II INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA | POL | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BEL 4
NCT05312710 Phase II APG-157 Safety and Efficacy of APG-157 in Head and Neck Cancer Recruiting USA 0
NCT05359692 Phase II INCAGN01876 + Retifanlimab INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Withdrawn USA 0
NCT05386550 Phase III Xevinapant Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Terminated USA | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | ARG 8
NCT05414032 Phase II AZD2936 Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN) Recruiting CAN 0
NCT05433116 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC Recruiting DEU 0
NCT05483400 Phase II Atezolizumab + Tiragolumab Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) Recruiting NLD 0
NCT05608369 Phase II Cisplatin Cisplatin + Vorinostat Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV) Not yet recruiting USA 0
NCT05678348 Phase I Pyrimethamine Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT05681039 Phase II Atezolizumab + Carboplatin + Tiragolumab Atezolizumab + Cisplatin + Tiragolumab Atezolizumab + Tiragolumab Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Recruiting USA 0
NCT05724602 Phase II Xevinapant Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA) Suspended SVN | NOR | NLD | ITA | IRL | GBR | FRA | ESP | DEU | BEL 0
NCT05743270 Phase II Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN Withdrawn USA | POL | GRC | GBR | FRA | ESP | DEU | CZE 0
NCT05784012 Phase Ib/II Dostarlimab-gxly + Niraparib Cisplatin + Dostarlimab-gxly + Niraparib Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (RADIAN) Recruiting ESP 0
NCT05814666 Phase II Pembrolizumab Danvatirsen + Pembrolizumab Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN) Recruiting USA | GBR 1
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DNK | CHE 0
NCT05879484 Phase Ib/II DS-3201b + Pembrolizumab Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS Not yet recruiting USA 0
NCT05909904 Phase II LBL-007 + Tislelizumab Tislelizumab BGB-A425 + Tislelizumab BGB-A425 + LBL-007 + Tislelizumab Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Recruiting USA | CAN | AUS 5
NCT05930938 Phase III Cetuximab Cetuximab + Xevinapant Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01) Suspended FRA 0
NCT05980000 Phase II Pembrolizumab + Ramucirumab Pembrolizumab Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2) Recruiting USA 0
NCT05980598 Phase II Pembrolizumab + TransCon TLR7/8 Agonist TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist Pembrolizumab TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201) Recruiting USA | POL | ITA | HUN | ESP | DEU 2
NCT06003231 Phase II Disitamab vedotin A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting USA | ITA | GBR | ESP | CAN | AUS 1
NCT06005324 Phase I Cisplatin Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Cetuximab + Paclitaxel Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer Recruiting USA 0
NCT06016920 Phase Ib/II Pembrolizumab + VB10.16 Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma Recruiting POL | NOR | HUN | GBR | FRA | ESP | DEU | CZE 0
NCT06046482 Phase II Cetuximab + Docetaxel + Hu5F9-G4 Cetuximab + Hu5F9-G4 + Pembrolizumab Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma Terminated USA 0
NCT06062420 Phase II Dostarlimab-gxly Dostarlimab-gxly + EOS-448 + GSK6097608 Dostarlimab-gxly + GSK6097608 Dostarlimab-gxly + EOS-448 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 Recruiting USA | TUR | ROU | POL | NOR | ITA | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CAN | BRA | ARG 4
NCT06082167 Phase II Pembrolizumab + XL092 Pembrolizumab Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) Recruiting USA | SVK | ROU | ITA | FRA | ESP | CZE | BRA | BGR | BEL | AUT | AUS | ARG 4
NCT06096038 Phase Ib/II iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Recruiting USA 0
NCT06110195 Phase I Carboplatin + Paclitaxel + Xevinapant Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer Active, not recruiting USA 0
NCT06129864 Phase III MEDI5752 A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) Recruiting USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT 8
NCT06145412 Phase II Cisplatin + Xevinapant A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer Active, not recruiting USA 0
NCT06150664 Phase I CTX-8371 A Phase 1 of CTX-8371 in Patients With Advanced Malignancies Recruiting USA 0
NCT06159621 Phase I LVGN3616 LVGN3616 + LVGN7409 CD40 Agonist and PD-1 Inhibitor in HNSCC Recruiting USA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 2
NCT06239220 Phase II Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC Recruiting USA 0
NCT06256588 Phase III Dostarlimab-gxly A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) Recruiting USA | TUR | SWE | ROU | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 7
NCT06295731 Phase II INBRX-106 + Pembrolizumab Pembrolizumab INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>=20 HNSCC (HexAgon-HN) Recruiting USA 0
NCT06332092 Phase II Cetuximab + FID-007 FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting USA 0
NCT06357858 Phase I Decitabine and Cedazuridine + Nivolumab ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck Withdrawn USA 0
NCT06366451 Phase I AZD2936 Pembrolizumab AZD7789 MEDI5752 PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC Recruiting USA 0
NCT06385080 Phase Ib/II Amivantamab-vmjw Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw + Paclitaxel A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4) Recruiting USA | GBR 3
NCT06448026 Phase II Cemiplimab + Cetuximab Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC). Not yet recruiting USA 0
NCT06496178 Phase III Methotrexate Cetuximab Docetaxel MCLA-158 A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients Recruiting USA | ISR | AUS | ARG 3
NCT06525220 Phase III Pembrolizumab MCLA-158 + Pembrolizumab A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer Recruiting USA | ISR | AUS | ARG 3
NCT06636734 Phase II Lovastatin + Pembrolizumab Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Not yet recruiting USA 0
NCT06648096 Phase Ib/II Afatinib Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (AFAN) Not yet recruiting ESP | DEU 0